Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the eastern cooperative oncology group

Cancer

Volumn 115, Issue 19, 2009, Pages 4504-4513

  Argiris, Athanassios ^a,i   Buchanan, Ashley ^b   Brockstein, Bruce ^c   Kolesar, Jill ^d   Ghebremichael, Musie ^e   Pins, Michael ^f   Hahn, Kristine ^d   Axelrod, Rita ^g   Forastiere, Arlene ^h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c NW Univ Evanston IL 60208 2710 USA   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e HARVARD UNIVERSITY   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Docetaxel; Head and neck cancer; Irinotecan; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; DOCETAXEL; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; PLATINUM; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; AGITATION; ANOREXIA; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISTANT METASTASIS; DIZZINESS; DRUG EFFICACY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GENE; GENOTYPE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; SYNCOPE; THROMBOSIS; TREATMENT RESPONSE; UGT1A1 GENE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCURONOSYLTRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349295970     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24528     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644-2652. (Pubitemid 46628471)
3. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562-3567.
4. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177. (Pubitemid 46954639)
5. Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006;32:583-587. (Pubitemid 44645022)
6. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-2362. (Pubitemid 30415821)
7. Hitt R, Amador ML, Quintela-Fandino M, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006;106:106-111. (Pubitemid 43032554)
8. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40:2071-2076. (Pubitemid 39165540)
9. Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007;13:3269-3275. (Pubitemid 46944912)
10. Lankisch TO, Schulz C, Zwingers T, et al. Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev. 2008;17:695-701.
11. Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother. 2005;6:85-92.
12. Murren JR, Davies M. Irinotecan and taxane combinations for non small-cell lung cancer. Clin Lung Cancer. 2001;2(suppl 2):S20-S25. (Pubitemid 32611390)
13. Bleickardt E, Argiris A, Rich R, et al. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther. 2002;1:646-651.
14. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434-1440. (Pubitemid 40315223)
15. Smith BD, Smith GL, Carter D, et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18:2046-2052. (Pubitemid 30324357)
16. Gallo O, Masini E, Bianchi B, et al. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33:708-714. (Pubitemid 34953350)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
18. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
19. Agresti A. Categorical data analysis. New York, NY: John Wiley & Sons; 1990.
20. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80-83.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;23:187-202.
23. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984;40:819-825.
24. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005;11:1226-1236. (Pubitemid 40175775)
25. Mercke Odeberg J, Andrade J, Holmberg K, et al. UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol. 2006;62:829-837. (Pubitemid 44521431)
26. Burtness B, Thomas L, Sipples R, et al. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer J. 2007;13:257-262.
27. Polyzos A, Kosmas C, Toufexi H, et al. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res. 2005;25:3559-3564. (Pubitemid 41105241)
28. Stathopoulos GP, Tsavdaridis D, Malamos NA, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol. 2005;56:487-491. (Pubitemid 41549150)
29. Sym SJ, Chang HM, Kang HJ, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol. 2008;63:1-8.
30. Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer. 2005;92:15-20. (Pubitemid 40188429)
31. Yamamoto N, Fukuoka M, Negoro SI, et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group study (WJTOG9803). Br J Cancer. 2004;90:87-92. (Pubitemid 38174944)
32. Lordick F, von Schilling C, Bernhard H, et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003;89:630-633. (Pubitemid 37076164)
33. Kurtz JE, Negrier S, Husseini F, et al. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology. 2003;50:567-570. (Pubitemid 36390571)
34. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-8654. (Pubitemid 46211507)
35. Numico G, Merlano M. Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol. 2002;13:331-333. (Pubitemid 34704989)
36. Lim SC, Park SY, Do NY. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep. 2003;10:1073-1079.
37. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369-3372.
38. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290-1295. (Pubitemid 47394168)
39. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13:3855-3859. (Pubitemid 47037591)